Localization of Glycine Receptors in the Human Forebrain, Brainstem, and Cervical Spinal Cord: An Immunohistochemical Review by Baer, Kristin et al.
Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 25  |  1
MOLECULAR NEUROSCIENCE
REVIEW ARTICLE
published: 04 November 2009
doi: 10.3389/neuro.02.025.2009
2006). In humans, missense and nonsense mutations in the GlyR 
α1 gene (GLRA1) and the GlyT2 transporter gene (SLC5A6) are 
the major cause of this disorder (Shiang et al., 1993; Rees et al., 
1994, 2001, 2006; Gomeza et al., 2003), although mutations in the 
GlyR β subunit (Rees et al., 2002), and the GlyR clustering protein 
gephyrin (GPHN; Rees et al., 2003) have also been reported. GlyRs 
containing the α3 subunit have increasing therapeutic importance, 
as they are involved in downstream signaling of inﬂ  ammatory pain 
in the spinal cord (Harvey et al., 2004) and may offer novel avenues 
for the treatment of inﬂ  ammatory pain. Despite these studies, the 
location of GlyR subunit combinations in human adult brain and 
spinal cord remain largely uncharacterized (Probst et al., 1986; Naas 
et al., 1991), and the biological and genetic basis of many cases of 
hyperekplexia and paroxysmal movement disorders remain unre-
solved (Harvey et al., 2008).
Early studies showed the presence of GlyR in rat and human 
cerebral cortex, although levels of IR were lower than those seen 
in spinal cord (Naas et al., 1991). GlyR-IR was prominent in apical 
dendrites of pyramidal neurons in layers III and IV (Naas et al., 
1991). GlyRs are also present in other higher cognitive areas such 
as the hippocampus, where they contribute to both short- and 
long-term plasticity (Keck and White, 2009), in the developing 
INTRODUCTION
Glycine receptors (GlyR) belong to the superfamily of ionotropic 
receptors that include GABAA, acetylcholine receptors and glutamate 
(Rajendra et al., 1997; Cascio, 2002; Colquhoun and Sivilotti, 2004). 
They are also part of the superfamily of ligand-gated ion channels, 
the Cys-loop receptors (Connolly and Wafford, 2004). Recently 
accumulated knowledge demonstrates that the receptor structure 
of the Cys-loop family has an important impact on the function of 
the receptor (Connolly and Wafford, 2004). GlyRs are important 
inhibitory receptors in the central nervous system, and are espe-
cially prominent in the brainstem and spinal cord (Altschuler et al., 
1986; Alvarez et al., 1997). GlyRs are strychnine sensitive and are 
involved in regulating inhibitory chloride inﬂ  ux through chloride 
channels to stabilize the resting potential of neurons. GlyRs form 
pentamers assembled from a range of subunits (currently α1–4, 
and β subunits), (Langosch et al., 1990; Grudzinska et al., 2005). In 
the human, only four known functional GlyR subunits have been 
identiﬁ  ed, α1–α3 and β (Lynch, 2004) which are most likely to exist 
in heteromeric αβ combinations. Defects in mammalian glycinergic 
neurotransmission can result in a complex motor disorder charac-
terized by an exaggerated startle reﬂ  ex and neonatal hypertonia, 
known as hyperekplexia (Andrew and Owen, 1997; Bakker et al., 
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Auckland, New Zealand). The University of Auckland Human 
Subject Ethics Committee approved the protocols used in these 
studies. For further details see Waldvogel et al. (2006). Microtome-
cut brain sections of adult human brain were processed for immu-
nohistochemical staining as previously described (Waldvogel et al., 
2006). In brief, the human brains were ﬁ  xed by perfusion through 
the basilar and internal carotid arteries, ﬁ  rst with phosphate-buff-
ered saline (PBS) with 1% sodium nitrite, followed by 15% forma-
lin in 0.1M phosphate buffer, pH 7.4. After the perfusion, blocks 
were dissected out and kept in the same ﬁ  xative for 24 h. These 
blocks were cryoprotected in 20% sucrose in 0.1 M phosphate 
buffer with 0.1% Na-azide for 2–3 days, and then in 30% sucrose in 
0.1 M phosphate buffer with 0.1% Na-azide for a further 2–3 days. 
Sectioning of the blocks was performed on a freezing microtome 
at a thickness of 50–70 µm. The sections were collected in PBS 
with 0.1% sodium azide (PBS-azide) and stored for immunohis-
tochemical processing.
PRIMARY ANTIBODIES
All antibodies used were dissolved in immunobuffer consisting of 
either 1% goat or 1% donkey serum in PBS with 0.2% Triton X-100 
and 0.4% thimerosal (Sigma). Three different GlyR antibodies were 
tested for the detection of GlyRs in the human brain. These were: 
(i)  the mouse monoclonal antibody mAb4a raised against 
amino acids 96–105 in the 48 kDa α1-subunit of the GlyR, 
and which also recognizes the 58 kDa β-subunit of the GlyR 
(Alexis Biochemicals; Pfeiffer et  al., 1984; Schroder et  al., 
1991; Kirsch and Betz, 1993);
(ii)  a mouse monoclonal antibody mAb2b raised against 
amino acids 1–10 of the 48 kDa GlyR α1 subunit (Alexis 
Biochemicals; Pfeiffer et al., 1984); and
(iii) a rabbit polyclonal antibody AB5052 (RGlyR) raised 
against a peptide from the N-terminus of human α1 
GlyR subunit (sequence of the immunizing peptide is 
ARSTKPMSPSDFLDKLMGC; manufacturer’s techni-
cal information) with cross reactivity to the α2 subunit 
(Chemicon, Temecula, CA, USA; Geiman et al., 2002). The 
rabbit polyclonal AB5052 was used mainly for double labe-
ling studies (see below), and has been used reliably to label 
GlyR clusters in rat spinal cord and brainstem (Geiman et al., 
2002; Liu and Wong-Riley, 2002; Rubio and Juiz, 2004), and 
human brain (Waldvogel et al., 2007).
The anti-GlyR antibodies used were directed to various dif-
ferent sequences of the GlyR subunits and detected either the 
α1 subunit only (mAb2b), the α1 and α2 subunits (AB5052), or 
recognized an epitope conserved in all known α and β subunits 
(mAb4a; Pfeiffer et al., 1984; Schroder et al., 1991; Kirsch and Betz, 
1993). The mAb4a and AB5052 antisera recognized the expected 
two protein bands (48 and 58 kDa) on Western blot of human basal 
ganglia tissue homogenates (Waldvogel et al., 2007). The staining 
patterns of the various GlyR antibodies were generally similar in the 
regions tested. The anti-GlyR antibodies produced similar patterns 
of staining except that the mAb4a which recognizes all subunits 
was consistently more intense than the other GlyR antibodies which 
selectively recognize α subunits.
neocortex (Flint et al., 1998), and in the mammalian amygdala of 
the limbic system (Danober and Pape, 1998; McCool and Botting, 
2000; Dudeck et al., 2003). In addition, GlyR signaling was detected 
in non-neuronal cells (den Eynden et al., 2009).
In our ongoing investigations, we have utilized immunohisto-
chemical staining methods (Waldvogel et al., 2006) to analyse the 
expression and synaptic localization of GlyRs in the human brain-
stem and spinal cord. The antibodies utilized in these studies pro-
duce a punctate immunolabelling pattern in the rat, cat or human 
brain (Triller et al., 1985, 1987; Kirsch and Betz, 1993; Todd et al., 
1996; Alvarez et al., 1997; Colin et al., 1998; Geiman et al., 2000, 
2002). In addition to GlyRs, we have described the   distribution 
of gephyrin in the human brain (Waldvogel et al., 2003, 2009), a 
multifunctional protein responsible for the clustering of GlyRs at 
inhibitory synapses (Fritschy et al., 2008).
Recently we reported on the distribution of GlyRs in the human 
brain basal ganglia (Waldvogel et al., 2007). The human brain basal 
ganglia are a group of large subcortical nuclei involved in the complex-
ity of motor and mood control. They include the striatum (caudate 
nucleus and putamen), the external (GPe) and internal (GPi) seg-
ments of the globus pallidus (GP), the substantia nigra (SN), which 
has two subdivisions, the substantia nigra pars compacta (SNc) and 
the substantia nigra pars reticulata (SNr), and also include the subtha-
lamic nucleus (Graybiel, 1995). The caudate and putamen project to 
the output nuclei of the basal ganglia, the GPe, GPi and the SNr. The 
substantia nigra pars compacta contains dopaminergic, pigmented 
neurons which project to various regions of the forebrain especially 
the striatum. The neurons of the substantia nigra pars reticulata are 
mainly GABAergic and project to the thalamus, superior colliculus 
and brainstem regions (Smith et al., 1998). The predominant inhibi-
tory receptors in the human basal ganglia are ionotropic GABAA and 
metabotropic GABAB receptors (Waldvogel et al., 1999, 2004), but 
there is convincing evidence from observations in animals (Sergeeva, 
1998; Darstein et al., 2000; Sergeeva and Haas, 2001) and in the human 
brain (Naas et al., 1991) that inhibitory GlyRs also exist in the mam-
malian basal ganglia. Also, there is evidence that glycinergic mecha-
nisms modulate dopaminergic, cholinergic and GABAergic functions 
in the striatum and the substantia nigra (Cheramy et al., 1978; Kerwin 
and Pycock, 1979; de Montis et al., 1982; Sergeeva, 1998; Darstein 
et al., 2000) and these mechanisms can be inﬂ  uenced by the action 
of ethanol (Darstein et al., 1997).
This work is a review article and summarizes these studies of 
the post-mortem human brain utilizing antibodies directed against 
GlyR subunits and immunohistochemical procedures to visualize 
the regional and cellular distribution of GlyRs in the forebrain and 
the various major nuclei of the basal ganglia, the striatum, globus 
pallidus, substantia nigra and the cervical spinal cord at the light and 
confocal laser scanning microscope levels. These investigations are 
speciﬁ  cally directed to investigate the distribution of GlyRs in these 
human brain regions in order to elucidate the role GlyRs may play 
in inhibitory mechanisms modulating human brain function.
IMMUNOHISTOCHEMICAL PROCEDURES
BRAIN TISSUE
For this study, the human brain tissue was obtained from the 
Neurological Foundation of New Zealand Human Brain Bank 
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 tetrahydrochloride (DAB; Sigma) and 0.01% H2O2 in 0.1 M phos-
phate buffer, pH 7.4, for 15–30 min to produce a brown reaction 
product. A nickel-intensiﬁ  ed procedure was also used in which 0.4% 
nickel ammonium sulphate was added to the DAB solution to pro-
duce a blue-black reaction product (Adams, 1981). The sections 
were washed in PBS, mounted on gelatin chrom-alum coated slides, 
rinsed in distilled water, dehydrated through a graded alcohol series 
to xylene, and coverslipped with DPX (BDH, Poole, UK).
Routinely a few sections were processed as control sections 
to determine nonspeciﬁ  c staining using the same immunohis-
tochemical procedures detailed above except that the primary 
antibody was omitted from the procedure. In addition, sections 
were stained for Nissl substance with Cresyl Violet according to 
standard techniques.
IMMUNOFLUORESCENT DOUBLE LABELING
For immunoﬂ   uorescent double-labeling confocal laser scan-
ning microscopy, sections were incubated in a cocktail of mono-
clonal and polyclonal antibodies (monoclonal antibody mAb4a 
diluted 1:2,000; polyclonal rabbit antibody AB5052 against GlyR 
  subunits diluted 1:500; monoclonal mAb3B11 against gephyrin 
diluted 1:1,000; polyclonal rabbit antibody against parvalbumin 
diluted 1:500; polyclonal rabbit antibody against calretinin diluted 
1:500). The sections were processed using the same procedure as the 
  single-labeled sections. They were incubated in primary antibod-
ies for 2–3 days on a shaker at 4°C, washed, and then incubated in 
species-speciﬁ  c ﬂ  uorescent secondary antibody directly linked to 
AlexaFluor 488 or AlexaFluor 594 (1:400; Molecular Probes) or CY3 
(1:500). Control sections where the primary antibody was omit-
ted showed no IR. The sections were washed, mounted on slides 
with Citiﬂ  uor (Agar Scientiﬁ  c, Stanstead, UK) or ProLongGold 
(Invitrogen), and viewed using a Zeiss LSM510 or Leica SP2 con-
focal laser scanning microscope. Confocal laser scanning micro-
scope digital images were collected and contrast optimized using 
Adobe Photoshop software. Linear methods were used to enhance 
image brightness and contrast for presentation, applied to all images 
with the same parameters unless otherwise indicated.
GlyR-IMMUNOREACTIVITY (IR) IN THE HUMAN FOREBRAIN, 
BRAINSTEM, AND CERVICAL SPINAL CORD
The principal aim of these studies was to immunohistochemically 
investigate the localization and distribution of GlyRs in the human 
forebrain, brainstem and cervical spinal cord at the regional and 
cellular levels. Sections from representative regions of the human 
brainstem and spinal cord were immunohistochemically labeled for 
GlyR subunits, and were microscopically examined to determine 
the distribution of speciﬁ  c immunoreactivities generated by these 
antibodies. Light and confocal laser scanning microscope analysis 
of the distribution of GlyR subunits revealed robust and punctate 
GlyR-IR in the human brainstem and spinal cord regions.
The antibodies assessed for these studies were selected to investi-
gate the staining patterns of GlyRs based on their staining properties 
in human tissue. The GlyR monoclonal antibody mAb4a produced 
the strongest signal with the least background and was used for the 
majority of the GlyR staining in this study. It is predominantly the 
results of the antibodies mAb4a and mAb2b that are presented in 
this paper, although some illustrations from the polyclonal rabbit 
Other primary antibodies used to identify various cell pheno-
types in the basal ganglia were as follows: 
(1)  Polyclonal rabbit anti-parvalbumin antiserum (SWANT, 
Bellinzona, Switzerland; PV-28, also named PV4064, manu-
facturer’s information) was produced in rabbits immunized 
with rat muscle parvalbumin. The antiserum against parval-
bumin was previously characterized by western blotting of 
mouse brain tissue (Schwaller et al., 2004; Collin et al., 2005), 
in which the serum recognized a single protein band of the 
appropriate molecular weight. The speciﬁ  city of the polyclo-
nal anti-parvalbumin antiserum was previously conﬁ  rmed by 
absorption experiments using puriﬁ  ed proteins and recombi-
nant rat parvalbumin (Xu et al., 2006).
(2)  Polyclonal rabbit anti-calretinin antiserum (SWANT, 
Bellinzona, Switzerland; 7699/4) was produced in rabbits 
immunized with recombinant human calretinin. The anti-
serum against calretinin was previously characterized by 
Western blotting of monkey and rat brain extracts (Schwaller 
et al., 1993), in which the serum recognized a single protein 
band of the appropriate molecular weight.
For the detection of gephyrin, the monoclonal mouse anti-
body mAb3B11 was used which was raised against the ﬁ  rst half of 
gephyrin’s E-domain (Synaptic Systems; Germany). The gephyrin 
antiserum recognized a single protein band (93 kDa) on Western 
blot of rat brain (manufacturer’s technical information), trans-
fected gephyrin variants (Smolinsky et al., 2008), and human brain 
(Waldvogel et al., 2009) and stained a pattern of protein distribu-
tion in the human brain that is identical with previous reports 
(Baer et al., 2003; Waldvogel et al., 2003).
SINGLE IMMUNOPEROXIDASE LABELING
Using standard immunohistochemical procedures, adjacent series 
of sections were selected and processed free-ﬂ  oating in tissue cul-
ture wells. Sections were washed in PBS and 0.2% Triton X-100 
(PBS-Triton) and pretreated for antigen retrieval using a protocol 
modiﬁ  ed from that of Fritschy et al. (1998), before being processed 
for immunohistochemistry. Sections for antigen retrieval were 
transferred to six-well tissue culture plates and incubated overnight 
in 0.1 M sodium citrate buffer, pH 4.5, and transferred to 10 ml 
of fresh sodium citrate buffer solution. Following this the sections 
were microwaved in a 650 W microwave oven for 30 s and allowed 
to cool before washing (3 × 15 min in PBS-Triton). The sections 
were then washed in PBS-Triton, incubated for 20 min in 50% 
methanol and 1% H2O2, washed again (3 × 15 min) in PBS-Triton, 
and incubated in primary antibodies for 2–3 days on a shaker at 
4°C. The mouse monoclonal antibody mAb2b was used at dilution 
1:2,000 and mouse monoclonal antibody mAb4a was used at a 
dilution of 1:2,000–1:5,000; the rabbit polyclonal antibody AB5052 
(RGlyR) was used at a dilution of 1:500–1:1,000. The primary anti-
bodies were washed off (3 × 15 min; PBS-Triton) and the sections 
incubated overnight in species-speciﬁ   c biotinylated secondary 
antibodies (1:500; Sigma; Jackson Laboratories). The secondary 
antibodies were washed off (3 × 15 min; PBS-Triton) and the sec-
tions incubated for 4 h at room temperature in ExtrAvidin, 1:1,000 
(Sigma). The sections were reacted in 0.05% 3,3′- diaminobenzidine Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 25  |  4
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antibody AB5052 (termed RGlyR) are included where appropri-
ate. The anti-GlyR antibodies demonstrated a  similar distribution, 
although mAb4a consistently produced a stronger signal probably 
due to recognizing all subunits of the GlyR whereas the others 
selectively recognized α subunits.
When the staining pattern of single labeled adjacent sections 
was compared, the staining pattern of the three antibodies mAb4a, 
mAb2b and RGlyR was essentially the same at both the regional 
and cellular level (Figures 1 and 2). In double labeling studies 
where both the rabbit anti-GlyR antibody and the mAb4a antibody 
were incubated together, the staining pattern was very similar and 
showed an overlapping distribution on neuronal cell membranes 
(Waldvogel et al., 2007).
GlyRs IN THE FIRST CERVICAL SEGMENT OF THE SPINAL CORD
The labeling of GlyRs was consistently high throughout the cervical 
spinal cord (Baer et al., 2003; Waldvogel et al., 2009). GlyR-IR was 
evident throughout the gray matter of the spinal cord (Figures 1A,B) 
and was especially intense in the dorsal (DH) and ventral horns 
(VH; Figures 1A,B). The neuropil of lamina II of the dorsal horn 
showed the most intense GlyR-IR in the spinal cord (Figures 1A,B). 
At high magniﬁ  cation a dense network of cell bodies and ﬁ  ne 
dendritic processes was evident with punctate GlyR-IR on their 
  membranes in lamina II and III (Baer et al., 2003). In the ventral 
horn, moderate to high levels of intense GlyR puncta were observed 
on cell bodies and dendritic processes (Baer et al., 2003).
GlyRs IN THE MEDULLA OBLONGATA
GlyR-IR produced a heterogeneous distribution in the gray matter of 
the middle and lower medulla oblongata (Baer et al., 2003; Waldvogel 
et al., 2009). The hypoglossal nucleus labeled with high intensities of 
GlyR-IR, and the dorsal motor nucleus of the vagus nerve consist-
ently showed moderate GlyR-IR (Baer et al., 2003). High levels of 
GlyR-IR were present in the spinal trigeminal nucleus; Sp5O in the 
lower pons, Sp5C in the lower medulla oblongata at the level of the 
pyramidal decussation (Figures 1C,D). The cuneate nucleus (Cu) 
and the gracile nucleus (Gr) demonstrated small patches of high 
GlyR-IR (Figures 2C,D). At the cellular level a dense network of 
intensely labeled punctate GlyR-IR outlining small and large sized 
dendritic processes was observed in both of these nuclei (Baer et al., 
2003). Similarly, neurons in the magnocellular region of the reticular 
formation in the medulla oblongata demonstrated GlyR-IR out-
lining the membranes of soma and processes (Figures 2E,F). The 
inferior olivary complex and the accessory olivary nuclei revealed 
moderate to high levels of GlyR-IR (Baer et al., 2003). At the cellular 
level, the inferior olivary complex and accessory olivary nuclei dis-
played high levels of punctate GlyR labeling on dendritic processes 
and neuronal cell bodies (Baer et al., 2003).
GlyRs IN THE BASAL GANGLIA
At low magniﬁ  cation the caudate nucleus (CN) and putamen (P) 
displayed a heterogeneous moderate to low level of labeling for 
GlyRs (Figures 1G,H) whilst the globus pallidus showed a relatively 
very low level of labeling (Waldvogel et al., 2007), and the substan-
tia nigra (SN) in the midbrain a relatively high level of labeling 
(Figures 1E,F). The caudate-putamen displayed a distinct hetero-
geneous pattern of staining with regions of very pale patches of 
FIGURE 1 | Regional localization of glycine receptors at the cervical level 
of the human spinal cord (A,B), pyramidal decussation in the lower 
medulla oblongata (C,D), substantia nigra (E,F) and basal ganglia at the 
level of the caudate-putamen (G,H) visualized by DAB staining of adjacent 
sections using monoclonal antibody mAb4a (A,C,E,G) and rabbit 
polyclonal antibody AB5052 (B,D,F,H). (A,B) Light macroscopic images of 
sections of the ﬁ  rst cervical segment of the spinal cord stained for GlyR with 
mAb4a (A) and AB5052 (B) antibody showing especially intense labeling in 
lamina II of the dorsal horn (DH) and moderate to high levels of GlyR-IR in the 
gray matter of the ventral horn (VH) and dorsal horn. (C,D) Macroscopic images 
of sections of the pyramidal decussation stained for GlyR with mAb4a (C) and 
AB5052 (D) antibody revealing patchy GlyR-IR in the gracile nucleus (Gr) and 
the cuneate nucleus (Cu) and intense GlyR-IR in the spinal trigeminal nucleus 
(Sp5C). (E,F) Macroscopic images of sections of the substantia nigra (SN) 
stained for GlyR with mAb4a (G) and AB5052 (H) antibody showing high levels 
of GlyR-IR in the regions of the substantia nigra pars compacta and the 
substantia nigra pars reticulata. (G,H) Macroscopic images of sections of the 
basal ganglia at the level of the caudate-putamen stained for GlyR with mAb4a 
(E) and AB5052 (F) antibody suggesting a heterogeneous distribution of GlyR 
in the caudate nucleus (CN) and putamen (P) separated by the internal capsule 
(IC). Scale bar = 2 mm in (A,B); 2.5 mm in (C,D); 0.5 cm in (E–H).Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 25  |  5
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both the cell bodies and primary dendrites of pigmented neurons. 
The distal dendrites of SNc neurons did not appear to be immu-
nolabeled (Waldvogel et al., 2007). The IR in the pars compacta 
region often highlighted groups of pigmented neurons scattered 
mainly throughout the dorsal tier. On closer inspection, not all 
pigmented neurons were coated with GlyRs and counts of the 
pigmented neurons indicated that approximately 80% of the pig-
mented neurons in the substantia nigra pars compacta showed IR 
for either mAb4a or RGlyR on their cell membranes (Waldvogel 
et al., 2007).
The large neurons of the substantia nigra pars reticulata (SNr) 
that were intensely labeled by GlyRs had elongated cell bodies 
approximately 30-µm long with long branching dendrites often 
with a bipolar orientation (Waldvogel et al., 2007). SNr neurons 
were generally more intensely labeled for GlyRs than the substantia 
nigra pars compacta neurons. High-resolution confocal laser scan-
ning microscopy revealed that the GlyRs were localized in clusters; 
the clusters were often conspicuously arranged in discrete circular 
patterns on the cell surface membranes of the soma and proximal 
dendrites of the pars compacta and pars reticulata neurons and 
proximal dendrites (Waldvogel et al., 2007).
At the cellular level, neurons in the periaqueductal grey area 
(Figures 2A,B) and the superior colliculus (Figures 2C–F) of the 
human substantia nigra demonstrated GlyR-IR on the cell surface 
membranes of the soma and proximal dendrites. In agreement with 
previous reports (Baer et al., 2003), GlyR ‘hot spots’ were detected 
(Figures 2 and 3).
GlyRs AND GEPHYRIN
We have shown previously that gephyrin is ubiquitously distributed 
in the human brain (Waldvogel et al., 2003) and associated with 
GlyRs in the human brainstem (Baer et al., 2003). Gephyrin-IR 
was observed in sections at the ﬁ  rst cervical segment of the human 
spinal cord (Figures 3H,K). Gephyrin- and GlyR-IR was evident 
throughout the gray matter of the spinal cord and was especially 
intense in the dorsal and ventral horns (Figures 1A,B; Baer et al., 
2003; Waldvogel et al., 2009). At high magniﬁ  cation a dense net-
work of cell bodies and ﬁ  ne dendritic processes was evident with 
punctate gephyrin- and GlyR-IR on their membranes in lamina 
I, II and III (Figures 3G–L; Baer et al., 2003). Table 1 illustrates 
the relative intensity of GlyR-IR and gephyrin-IR in the human 
medulla oblongata and spinal cord (Baer et al., 2003; Waldvogel 
et al., 2009).
CHEMICAL CHARACTERISTICS OF GlyR IMMUNOREACTIVE
 NEURONS IN THE HUMAN BASAL GANGLIA
Various markers were used to determine the chemical phenotype 
of cells that displayed GlyR IR in the basal ganglia (Waldvogel et al., 
2007). Double labeling immunohistochemical studies were performed 
using markers to striatal interneurons: cholineacetyltransferase, par-
valbumin, calretinin and neuropeptide Y in order to further character-
ize which striatal interneurons had GlyRs on their surface membranes 
(Waldvogel et al., 2007). The substantia nigra pars compacta neurons 
were recognized by their neuromelanin pigmentation.
Previously, six different types of neurons were identiﬁ  ed in the 
striatum on the basis of cellular and dendritic morphology, chemi-
cal neuroanatomy, and GABAA receptor subunit conﬁ  guration 
FIGURE 2 | Glycine receptor labeling on neurons in the human midbrain 
and medulla oblongata visualized by DAB staining of adjacent sections 
using monoclonal antibody mAb4a (A,C,E,G) and monoclonal antibody 
mAb2b (B,D,F,H). (A,B) Neurons in the periaqueductal grey area of the 
midbrain showing high levels of punctate GlyR-IR along their soma and 
processes, revealing similar IR patterns using mAb4a (A) or mAb2b 
(B). (C,D) Neurons in the superior colliculus of the midbrain immunoreactive for 
mAb4a (C) and mAb2b (D) demonstrating GlyR-IR outlining the membranes of 
soma and processes. (E,F) Neurons in the magnocellular region of the reticular 
formation in the medulla oblongata immunoreactive for mAb4a (E) and mAb2b 
(F) revealing GlyR-IR along the neuronal soma and processes. (G,H) High levels 
of immunoreactive GlyR are present on neurons in the hypoglossal nucleus of 
the upper medulla stained for mAb4a (G) and mAb2b (H). Scale bar = 50 µm in 
(D) applies to (C–F); 10 µm in H [applies to (A,B,G,H)].
staining surrounded by a more densely staining background which 
resembled the striosome and matrix compartmental organization 
of the striatum (Figures 1G,H).
Neurons in both the pars compacta and pars reticulata regions 
of the substantia nigra were immunoreactive for GlyRs. Both the 
mAb4a and RGlyR antibodies stained most intense on the pars 
reticulata neurons and less intense on the pigmented pars compacta 
neurons (Figures 1E,F; Waldvogel et al., 2007). In the substantia 
nigra pars compacta intense IR was localized in the region of the 
pigmented neurons (Waldvogel et al., 2007) and was observed on Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 25  |  6
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of the striatal GlyR-IR positive neurons were   double labeled with 
parvalbumin, corresponding to type (i) neurons (Figures 3A–C; 
Waldvogel et al., 2007).
Previously we demonstrated that the globus pallidus has a mixed 
population of GlyR positive neurons that may represent different 
types of interneurons and possibly includes a subpopulation of 
the projection neurons (Waldvogel et al., 2007). Small numbers 
of GlyR positive pallidal neurons were labeled with parvalbumin 
or calretinin (Figures 3D–F). Most neurons in the human globus 
pallidus are labeled with parvalbumin or calretinin (Waldvogel 
et al., 1999), therefore the low number of the GlyRs positive neu-
rons double labeled with parvalbumin or calretinin would suggest 
they are not projection neurons, but may be local interneurons 
(Waldvogel et al., 2007).
CONTEXTUAL SUMMARY OF IMMUNOHISTOCHEMICAL 
FINDINGS
Using immunohistochemical methods at the light and confocal 
laser scanning microscopic levels, our results suggest that GlyRs are 
widely distributed in the human forebrain, brainstem, and cervical 
spinal cord. The methods used were optimized for structural tissue 
preservation and receptor stability of the postmortem human brain 
to limit background staining and lipofuscin artifacts (Waldvogel 
et al., 2006).
ANTIBODY CHARACTERIZATION
It is established that mAb2b- and 4a-IR represent postsynaptic 
structures (Triller et al., 1985; Altschuler et al., 1986) and also 
intracellular sites of GlyR protein synthesis, transport and aggre-
gation (Hoch et al., 1989). Sequence comparison of human and 
rat GlyR cDNAs reveals a complete conservation of the epitope for 
the mAb4a antibody (Schroder et al., 1991). In rat brain, Mab4a 
produces both punctate and diffuse somatic labeling, suggesting 
that the Mab4a antigens are not restricted to postsynaptic mem-
brane specializations (Kirsch and Betz, 1993). GlyR, using mAb4a, 
has demonstrated localization of GlyR at postsynaptic sites on 
human cortical neurons (Naas et al., 1991). Intracellular labeling 
was also reported for the anti-GlyR AB5052 (Geiman et al., 2002). 
FIGURE 3 | High-resolution confocal laser scanning microscopy images 
of neurons in the substantia nigra pars reticulata (A–C), putamen (D–F), 
and ﬁ  rst cervical segment of the spinal cord (G–L) of the human CNS 
double-labeled for GlyR (left column) and other cell markers (middle 
column) with combined images shown in the right column. (A–C) 
Neuron in the substantia nigra pars reticulata is labeled red for GlyR [mAb4a 
in (A), arrow] and immunopositive for rabbit anti-parvalbumin [green in (B)], 
green unlabeled parvalbumin processes in the picture resemble axon 
bundles, combined images in (C). (D–F) Neuron in the putamen that is 
outlined with GlyR-IR [mAb4a, red in (D), arrow] is labeled with rabbit anti-
calretinin immunoreactivity [green in (E)], combined images in (F). (G–I) 
Large neuron in the spinal cord that is outlined with rabbit anti-GlyR 
immunoreactivity [red in (G)] is labeled with mouse anti-gephyrin 
immunoreactivity [green in (H)], combined images in (I). Note the high 
degree of overlap of both markers, exempliﬁ  ed by the arrow highlighting the 
colocalized IR patterns. (J–L) High magniﬁ  cation of a process of a large 
motoneuron in the cervical spinal cord that shows punctate GlyR-IR [red in 
(J)] and punctate gephyrin-IR [green in (K)] demonstrating the high degree of 
colocalization of the GlyR and gephyrin IR patterns [yellow in (L)]. Lf in (C) and 
(I) indicates lipofuchsin autoﬂ  uorescence in the cell body. Scale bar = 25 µm 
in (C) [applies to (A–C)], (F) [applies to (D–F)]; (G) [applies to (G–I)], and (J) 
[applies to (J–L)].
(Waldvogel et al., 1999). We determined that GlyRs are localized 
predominantly to interneurons characterized neurochemically by IR 
for three of these six striatal neuron types (cholineacetyltransferase, 
parvalbumin, or calretinin; Waldvogel et al., 2007). Only very few 
Table 1 | Relative intensity of GlyR-IR and gephyrin-IR in the human 
medulla oblongata and spinal cord.
Brain region  GlyR-IR  Gephyrin-IR
Dorsal motor nucleus of the vagus nerve  +++  +++
Hypoglossal nucleus  ++++  +++
Solitary nucleus  ++  ++
Gracile nucleus  +++  ++
Spinal trigeminal nucleus  ++++  +++
Accessory olivary nuclear complex  ++++  +++
Inferior olive  +++  +++
Lateral reticular nucleus  ++  ++
Spinal cord lamina II  ++++  ++++
Spinal cord dorsal horn  ++++  +++
Spinal cord ventral horn  ++++  +++
+, weak levels of IR; ++, moderate levels of IR; +++ high levels of IR; ++++, most 
intense levels of IR.Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 25  |  7
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Although the receptor clusters are mainly  postsynaptic a  proportion 
of   extrasynaptic and cytoplasmic staining is observed (Levi et al., 
1999; Dumoulin et al., 2000). Using the antibodies Mab2b, Mab4a, 
and AB5052, it is not possible to exclusively detect the GlyR β 
subunit, which contains the gephyrin binding domain (Meyer 
et al., 1995) or to differentiate between α2 and/or α3 subunit-
containing GlyRs. To establish whether gephyrin is only associated 
with β subunit containing GlyRs in human brain, differential stud-
ies using β, α2 and α3 subunit-speciﬁ  c antibodies are required. 
These additional GlyR subunit-speciﬁ  c antibodies are not yet 
available.
DISTRIBUTION OF GlyRs IN THE FOREBRAIN, BRAINSTEM, AND 
CERVICAL SPINAL CORD OF THE HUMAN BRAIN
The major ﬁ  ndings in this study are that GlyRs are highly expressed 
on various subpopulations of neurons in the different nuclei of the 
forebrain, brainstem, and cervical spinal cord of the human brain 
(Baer et al., 2003; Waldvogel et al., 2007, 2009). In the forebrain, 
GlyR IR is most abundant in the substantia nigra, and is found on 
particular interneuronal cell types in the striatum (Waldvogel et al., 
2007). Furthermore, GlyR-IR was detected scattered throughout 
the globus pallidus and substantia nigra, and was also localized to 
medullary laminae regions surrounding the two segments of the 
globus pallidus.
At the regional level, the most intense staining was observed in 
the dorsal and ventral horns of the spinal cord, the spinal trigeminal 
nuclear complex, and the motor nuclei associated with the auto-
nomic nervous system such as the dorsal motor nucleus of the 
vagus nerve and motor cranial nerve nuclei such as the hypoglossal 
nucleus. These areas revealed intense GlyR labelling and there-
fore glycinergic inhibitory control of this nucleus is intense and 
possibly predominant. The patches of high IR in the cuneate and 
gracile nuclei may be associated with particular sensory inputs as 
the inputs to these nuclei are all topographically organized (Baer 
et al., 2003). Other brainstem nuclei such as the inferior olivary 
complex displayed moderate to high levels of GlyR-IR (Waldvogel 
et al., 2007).
The substantia nigra contained the highest levels of GlyR-IR 
in the human basal ganglia. High levels were observed in the 
region of the substantia nigra pars compacta. On closer inves-
tigation the GlyR-IR was localized on pigmented neurons and 
dendritic processes in the substantia nigra pars compacta region. 
Approximately 80% of the pigmented neurons had GlyRs located 
on their cell bodies and proximal dendrites. This would suggest 
that a large number of dopaminergic neurons possess GlyRs. This 
may indicate that the dopaminergic neurons of the substantia 
nigra pars compacta may be divided into different subgroups 
depending on the various receptor types which are expressed 
on their cell membranes (Waldvogel et al., 2007). The neurons 
of the substantia nigra pars reticulata were intensely reactive for 
GlyRs. These were large rounded or elongated neurons with long 
branching neurons characteristic of the large projection neurons 
of the substantia nigra pars reticulata. In the human striatum, 
GlyRs are localized predominantly to interneurons characterized 
neurochemically by IR for three of these six striatal neuron types 
(choline acetyltransferase, parvalbumin, or calretinin) (Waldvogel 
et al., 2007).
CELLULAR AND SUBCELLULAR GlyRs LOCALIZATION
At the cellular level, GlyR-IR was present on the plasma membranes 
of the soma and dendrites of neurons throughout the human sub-
stantia nigra, pons, medulla oblongata and cervical spinal cord 
(Baer et al., 2003; Waldvogel et al., 2007, 2009). Using light micro-
scopy, punctate labeling for GlyRs was observed on the membranes 
of neuronal somata and processes.
Confocal laser scanning microscopy revealed GlyR ‘hot spots’ 
(brightly stained puncta) reﬂ  ecting synaptic localization and aggre-
gation (Grunert and Wassle, 1993; Kirsch et al., 1996). The confocal 
laser scanning microscopy data in the human are consistent with 
GlyRs as observed in rat spinal cord (Geiman et al., 2002). In addi-
tion to GlyR cluster ‘hot spots,’ GlyR-IR was observed along the entire 
length of neuronal membranes. A similar observation was reported 
for cat spinal cord ventral horn neurons where the density and topo-
graphical organization of GlyR clusters varied in different neuronal 
types and in different dendritic regions (Alvarez et al., 1997).
COMPARING THE DISTRIBUTION OF GlyRs IN HUMAN AND RODENT 
BRAINSTEM AND SPINAL CORD
The current data show that the general distribution of GlyR  subunits 
detected in the human rostral and caudal pons, rostral medulla 
oblongata and the cervical spinal cord are generally in good agree-
ment with immunohistochemical and immunoenzymatic electron 
microscopy studies in the rat brainstem and spinal cord (Triller 
et al., 1985, 1987; van den Pol and Gorcs, 1988; Rampon et al., 1996; 
Alvarez et al., 1997; Geiman et al., 2002). The subcellular distribu-
tion of GlyRs in the mammalian retina has also been examined 
(Wässle et al., 1998). Using in situ hybridization techniques, GlyR 
mRNAs were detected in somata and dendrites of most neurons 
of the ventral horn of rat spinal cord (Racca et al., 1997); and in 
the rat spinal trigeminal nucleus, principal trigeminal nucleus, 
gracile and cuneate nuclei (Sato et al., 1991). Another rat brain 
study showed high levels of IR for the neurotransmitter glycine in 
the hypoglossal nucleus, gracile nucleus, spinal trigeminal nucleus 
and raphe nucleus (Rampon et al., 1996). The GlyR-IR which we 
have detected in the human is in agreement with these studies in 
the rat brain (Table 2).
GEPHYRIN INVOLVEMENT
Numerous studies have revealed that gephyrin is present at gly-
cinergic and GABAergic synapses (Fritschy et al., 2008). Virtually 
complete colocalization of GlyR-IR and postsynaptic gephyrin-IR 
has been established in the ventral horn of rat spinal cord (Triller 
et al., 1985, 1987; Todd et al., 1995, 1996; Colin et al., 1998). Another 
study suggested that most GlyRs in the rabbit retina colocalize 
with gephyrin (Zucker, 1998). Previously we demonstrated that 
gephyrin is widely distributed in the human brain and spinal cord, 
and that a large proportion of the GlyRs in the brainstem and spi-
nal cord show punctate IR that co-localizes with gephyrin (Baer 
et al., 2003; Waldvogel et al., 2003, 2009). The studies reviewed here 
establish the association of gephyrin and GlyRs in human brain-
stem and spinal cord indicating an association of gephyrin and 
GlyRs, implicating similar functions for gephyrin in human brain 
as that reported for rodent brain. Thus, gephyrin is likely to play a 
fundamental role in the organization of major types of inhibitory 
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Studies in rodents have revealed that gephyrin directly interacts 
with key regulators of microﬁ  lament dynamics, namely proﬁ  lin I 
and IIa and microﬁ  lament adaptors of the mammalian enabled 
(Mena)/vasodilator stimulated phosphoprotein (VASP) family 
(Giesemann et al., 2003). This interesting link may play an impor-
tant role in receptor density and dynamics at inhibitory synapses 
including activity-dependent remodeling of synaptic structures 
(Neuhoff et al., 2005). Although the scenario in human CNS is 
not known, high-resolution microscopy analysis suggested that 
not all GlyR α1 subunit-IR co-localizes with gephyrin, indicating 
that there may be other mechanisms involved in GlyR localization, 
presumably at presynaptic or extrasynaptic sites. The distribution 
of other major GlyR subtypes in human brain (α2, α3) remains 
to be determined.
Recent exciting data revealed that gephyrin and the cell adhe-
sion molecule neuroligin 2 interact and that deletion of neuroligin 
2 in mice disturbs glycinergic synaptic transmission (Poulopoulos 
et al., 2009). Neuroligins are important for the assembly of synaptic 
specializations, and complexes of neuroligin 2, gephyrin and col-
lybistin are sufﬁ  cient for cell-autonomous clustering of inhibitory 
neurotransmitter receptors (Poulopoulos et al., 2009). The role 
of neuroligins at inhibitory synapses in the human CNS requires 
further attention, but these recent ﬁ  ndings in rodents demonstrate 
that neuroligins can be regarded as important organizer proteins 
at postsynaptic glycinergic synapses.
Furthermore, gephyrin has multiple functions and is required 
for the biosynthesis of molybdenum cofactor (Feng et al., 1998; 
Fritschy et al., 2008). In an extensive search for human gephyrin 
transcript heterogeneity, we identiﬁ  ed neuronal gephyrin isoforms 
created from the alternative splicing of ﬁ  ve exons, also termed 
cassettes (C3, C4A–D) in the central linker region of the protein 
(Rees et al., 2003). The biological role of these gephyrin isoforms 
is not clear. At least one of these variants (cassette C3) is con-
stitutively spliced into non-neuronal gephyrin (Rees et al., 2003), 
but   otherwise the biological role of this neuronal heterogeneity 
is unclear. This is particularly true since most known interactors 
of gephyrin, including GlyR β, proﬁ  lins, Mena/VASP (Giesemann 
et al., 2003) and collybistin (Harvey et al., 2004) all bind to the C-
terminal MoeA homology domain. One hypothesis is that gephyrin 
cassettes may create or destroy sites for additional protein–pro-
tein interactions, perhaps controlling the accumulation of speciﬁ  c 
signalling pathways or cytoskeletal interactions in a brain-region 
speciﬁ  c manner. Also, these isoforms might play a role in GlyR 
clustering and/or might be differentially expressed during develop-
ment and/or in healthy versus diseased brain tissue. In addition, 
deﬁ  ned gephyrin isoforms might be selectively distributed to syn-
aptic or extrasynaptic sites and/or might be enriched at glycinergic 
synapses. Future work will elucidate whether gephyrin-/GlyR-IR 
patterns are changed by neuropathological disorders, and whether 
these IR patterns could represent novel biomarkers or indicators 
for neurodegenerative disease processes, by comparing and con-
trasting the immunoreactive patterns observed between normal 
and neuropathological brain samples. Also, given the limitations of 
immunoreactive approaches, future work will evaluate the develop-
ment of other technology platforms (for example, Quantum dot 
nanotechnologies) to enhance detection speciﬁ  city for GlyR.
FUNCTIONAL CONTEXT AND LINKAGES
The source of the neurotransmitter glycine which presumably acts 
on the GlyRs found in the human basal ganglia is not clear, but 
studies in the rat show that glycinergic IR terminals are present in 
regions of the ventral pallidum and basal forebrain (Rampon et al., 
1996). This may indicate that other regions of the basal ganglia such 
as the lateral medullary lamina between the putamen and external 
segment of the globus pallidus and the medial medullary lamina 
between the external segment of the globus pallidus and internal 
segment of the globus pallidus examined previously (Waldvogel 
et al., 2007) in the human basal ganglia may also be innervated by 
Table 2 | Comparison of the distribution of relative intensity of GlyR-IR in human and rodent brainstem and spinal cord (van den Pol and Gorcs, 
1988; Rampon et al., 1996; Baer et al., 2003).
Brain region  GlyR-IR on cell   GlyR-IR on processes   GlyR-IR on cell   GlyR-IR on
  bodies in human  in human  bodies in rodent  ﬁ  bers in rodent
Dorsal motor nucleus of the vagus nerve  ++  +++ 0  to  +  ++
Hypoglossal nucleus  +++  ++++  ++  ++++
Solitary nucleus  ++  ++  +  ++
Gracile nucleus  +++  +++  ++  +++
Spinal trigeminal nucleus  ++++  ++++  ++ to ++++  +++
Cuneate nucleus   +++  +++  +  +++
Locus coeruleus  ++  ++++ 0  to  +  +++
Dorsal raphe nucleus  +++  +++ 0  to  +  ++
Accessory olivary nuclear complex  ++  ++++  +++  ++++
Inferior olive  +++  +++  +++  ++++
Lateral reticular nucleus  +  ++  ++  +++
Spinal cord lamina II  ++++  ++++  ++ to ++++  ++ to ++++
Spinal cord dorsal horn  +++  ++++  ++ to ++++  ++ to ++++
Spinal cord ventral horn  +++  ++++  ++ to ++++  ++ to ++++
0, no detectable IR; +, weak levels of IR; ++, moderate levels of IR; +++ high levels of IR; ++++, most intense levels of IR.Frontiers in Molecular Neuroscience  www.frontiersin.org  November 2009  | Volume 2  |  Article 25  |  9
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glycinergic neurons. Since the greatest concentration of glycine 
and GlyRs are predominantly found in the brainstem it is possible 
that nuclei in the brainstem may be the source of the glycinergic 
input to the basal ganglia.
Our ﬁ  ndings, consistent with ﬁ  ndings in the rat (Darstein et al., 
2000), suggest that GlyRs are found on cholinergic interneurons 
in the human striatum (Waldvogel et al., 2007). Functional stud-
ies in the rat striatum have demonstrated that GlyRs can be acti-
vated within the striatum and that glycine application can induce 
acetylcholine release in the striatum (Darstein et al., 1997, 2000). 
Therefore the same mechanism may also operate in the human 
striatum. In addition, dopamine can be released in the striatum 
by application of glycine (Yadid et al., 1993) and is blocked by 
strychnine. Also, strychnine-sensitive glycinergic responses have 
been recorded in the rat striatum on both large cholinergic neurons 
and on GABAergic medium spiny neurons. One study has also 
established that ethanol can inhibit glycine induced responses in the 
rat striatum (Darstein et al., 1997), suggesting that glycine might 
present a new site for the functional effect of alcohol.
The pharmacological and physiological role of glycine in the 
substantia nigra is still unclear but studies in rats and cats have 
identiﬁ  ed various effects of glycine in the substantia nigra includ-
ing depression of dopamine neuron activity and reduced efﬂ  ux of 
dopamine in the caudate nucleus (Cheramy et al., 1978; de Montis 
et al., 1982). In contrast, other studies demonstrated an increase 
of dopamine efﬂ  ux in the substantia nigra with glycine application 
(Kerwin and Pycock, 1979), as well as glycine mediated effects of 
GABA transmission in the VTA region (Ye et al., 2004). Another 
study has implicated the role of glia as being a source of extracel-
lular glycine which can act on GlyRs in the substantia nigra pars 
reticulata (Dopico et al., 2006).
Defects in mammalian glycinergic neurotransmission at post 
and presynapse can result in a paroxysmal motor disorder, hyper-
ekplexia (for review see Harvey et al., 2008), and the GlyR alpha3 
subunit is an essential target for inﬂ  ammatory pain sensitization 
(Harvey et al., 2004). However, the locations of GlyR subunit com-
binations in human adult brain and spinal cord remain largely 
uncharacterized (Naas et al., 1991), and the biological and genetic 
basis of many cases of hyperekplexia and paroxysmal movement 
disorders remain unresolved. In addition, there is little data evaluat-
ing the GlyR and glycine presence in neurodegenerative diseases. 
Although GlyRs are changed in some pathological conditions (e.g. 
in the substantia nigra in Parkinson’s disease), the neuropharma-
cology of the glycine system is still poorly understood (Lloyd et al., 
1983). Moreover, glycine concentrations in Huntington’s disease 
patients were higher compared to controls as reported for analysis 
of platelets (Reilmann et al., 1997), and cerebrospinal ﬂ  uid (Nicoli 
et al., 1993). It is not known which metabolic defect might be 
responsible for the changes in glycine levels in Huntington’s disease, 
but the link to the N-methyl-d-aspartate subclass of ionotropic 
glutamate receptors (NMDARs), which possess a glycine binding 
site, and NMDARs excitoxicity in Huntington’s disease has been 
suggested (Reilmann et al., 1997; Fan and Raymond, 2007).
Finally, the need to increase our understanding of neuroinhibi-
tory receptor distribution and function including GlyRs in healthy 
and diseased human brain tissue is reﬂ  ected in the potential to 
create new pharmacological drugs for different neuropsychiatric 
disorders based on agonist activity at inhibitory neurotransmitter 
receptors. In summary, we provide evidence for the localization of 
GlyRs in neuronal populations in various regions throughout the 
human forebrain, brainstem, and cervical spinal cord. GlyRs are 
localized especially on cholinergic and calretinin positive neurons 
in the striatum and globus pallidus, as well as in high concentra-
tions within the intermedullary laminae of the globus pallidus and 
the substantia nigra. High levels of GlyRs are also found through-
out the substantia nigra where previous studies have implicated 
GlyRs in the modulation of dopaminergic function. It is postu-
lated from previous studies that glycinergic mechanisms that act 
on glycine ion channel receptors are involved in the modulation of 
cholinergic, dopaminergic and GABAergic pathways in the basal 
ganglia. Further studies are required to establish GlyR heteroge-
neity in human brain using additional subunit-speciﬁ  c anti-GlyR 
antibodies. The clustering protein gephyrin directly interacts with 
GlyRs, and the role of gephyrin and its isoforms remains elusive 
with regard to the mechanisms of synaptic localization, dynamic 
receptor clustering and GlyR heterogeneity in human brain. Future 
studies are essential for establishing the biological context and basic 
neuroscience principles of human glycinergic neuroinhibition in 
normal and neuropathological conditions.
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